Comparison of nalbuphine and buprenorphine as adjuvants to ropivacaine in interscalene brachial plexus block

A COMPARATIVE CLINICAL STUDY BETWEEN NALBUPHINE AND BUPRENORPHINE AS AN AJUVANT TO ROPIVACAINE IN ULTRASOUND GUIDED INTERSCALENE BRACHIAL PLEXUS BLOCK

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/031818

Enrollment

Registered

2021-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S420- Fracture of clavicle Health Condition 2: S424- Fracture of lower end of humerus Health Condition 3: S423- Fracture of shaft of humerus Health Condition 4: S422- Fracture of upper end of humerus

Interventions

Intervention1: NALBUPHINE: AS AN AJUVANT TO ROPIVACAINE IN ULTRASOUND GUIDED INTERSCALENE BRACHIAL PLEXUS BLOCK Control Intervention1: BUPRENORPHINE: AS AN AJUVANT TO ROPIVACAINE IN ULTRASOUND GUIDED

Eligibility

Inclusion criteria

Inclusion criteria: American Society of Anaesthesiologists (ASA) physical status I and II scheduled for upper limb surgery

Exclusion criteria

Exclusion criteria: Any neurological deficit, peripheral neuropathies, myopathies or chronic pain in the operative limb. History of anaphylaxis to local anaesthetics or known allergy to any of the study drugs to be used. Any history of bleeding diathesis or coagulation abnormalities. Any skin infection or local disease at the needle insertion site. BMI more than 35kg/sq-m, failure to achieve adequate block within 30 mins of administration.

Design outcomes

Primary

Measure	Time frame
Time to onset of sensory and motor block. Duration of sensory and motor block. Duration of analgesiaTimepoint: Time to onset of sensory and motor block. Duration of sensory and motor block. Duration of analgesia	—

Secondary

Measure	Time frame
Pain scores Adverse effects- Hypotension, Bradycardia, Tachycardia, Hypoxemia, Sedation, Nausea, Vomiting, Pruritis, Skin Rash, Dry mouth, DyspneaTimepoint: Pain assessed by Visual Analogue scale Hypotension(noninvasive blood pressure less than 20% of baseline) Bradycardia(heart rate less than 60beats/minute) Tachycardia(heart rate more than 100beats/minute) Hypoxemia(oxygen saturation less than 90%) Sedation assessed by Modified Ramsay sedation scale Nausea and vomiting assessed by Nausea and vomiting scale	—

Measure

Time frame

Pain scores Adverse effects- Hypotension, Bradycardia, Tachycardia, Hypoxemia, Sedation, Nausea, Vomiting, Pruritis, Skin Rash, Dry mouth, DyspneaTimepoint: Pain assessed by Visual Analogue scale Hypotension(noninvasive blood pressure less than 20% of baseline) Bradycardia(heart rate less than 60beats/minute) Tachycardia(heart rate more than 100beats/minute) Hypoxemia(oxygen saturation less than 90%) Sedation assessed by Modified Ramsay sedation scale Nausea and vomiting assessed by Nausea and vomiting scale

—

Countries

India

Contacts

Public ContactAnitha A

Kempagowda institute of medical science

drvinodcn@gmail.com9886882521

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026